ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2517

The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease

Erdem Bektas1, Rabia Deniz2, Zeliha Emrence3, Sema Sırma Ekmekci3, Neslihan Abacı3, Shirkhan Amikishiyev4, Yasemin Yalçınkaya4, Bahar Artim Esen4, Murat Inanç5 and Ahmet Gul6, 1Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, 2University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, 3Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Meeting: ACR Convergence 2023

Keywords: Behçet's Syndrome, longitudinal studies, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs) have been claimed in the pathogenesis of BD [1]. We herein aimed to investigate the potential relationship between the NETosis findings and local and systemic disease activity in BD.

Methods: The study group was consisted of orally and/or systemically active BD patients who met the ISG criteria and healthy individuals. The patients with additional inflammatory conditions or using biologic agents were excluded. Serum and saliva samples were collected from the patients during their active (active oral ulcer and/or systemic manifestations) and remission (no manifestations, normal acute phase reactants) periods cross-sectionally. Some of them were followed also longitudinally. Cell-free DNA (cf-DNA), neutrophil elastase (NE), myeloperoxidase (MPO) and citrullinated histon-3 (cit-H3) levels were measured as NETosis findings, and the results were adjusted according to the peripheral blood neutrophil counts (as the amount of biomarker per 1 million neutrophils). Unadjusted and adjusted levels were evaluated.

Results: The study group consisted of 30 active and 18 inactive BD patients as well as 10 healthy controls. Serum samples were collected from all active patients, and saliva samples were obtained from 15 orally active patients, while 18 serum and 7 saliva samples were obtained when they were in remission. Demographic and cumulative clinical characteristics of the patients are shown in Table 1. In active BD, serum cf-DNA and serum NE levels were found to be high (p≤0.001, p< 0.05), whereas adjusted serum MPO and adjusted serum cit-H3 levels were found to be low (p≤0.001, p≤0.01). In inactive BD, serum NE level were higher than controls (p< 0.05), while serum MPO, adjusted serum MPO and adjusted serum cit-H3 levels were lower than controls (p< 0.05, p≤0.001, p< 0.05, respectively). No difference was found in salivary NETosis findings between patient groups and controls (Figure 1). Serum cf-DNA and saliva cf-DNA levels showed a decrease in longitudinal follow-up towards remission (p≤0.01, p< 0.05) (Figure 2). Serum cf-DNA and saliva cf-DNA positively correlated with C-reactive protein and erythrocyte sedimentation rate, while adjusted serum MPO and adjusted serum cit-H3 negatively correlated (p< 0.05).

Conclusion: NETosis findings showed changes in association with systemic and/or local activity of BD patients in relation to the disease manifestations. Especially, serum and saliva cf-DNA levels potentially indicated the local and systemic disease activity, and serum NE levels were high in both active and inactive periods. The mechanism of the low serum MPO and cit-H3 levels, particularly in the active patients warrants further investigation. Changes of the findings after adjustment of the results according to the peripheral blood neutrophil counts may indicate that the NETosis findings detected in serum could be related to high neutrophil turnover in the active phase of the disease. Further studies are needed to clarify the biomarker potential of NETosis findings in BD.

Supporting image 1

Table 1. Demographic and cumulative clinical characteristics of the active and inactive patients. Data show median (IQR) or mean ± SD as appropriate. Abbreviations: BD, Behcet disease; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; N, number of available patients; n, number of meet criteria; SD, standard deviation; TNFi, tumor necrosis factor inhibitor

Supporting image 2

Figure 1. The levels of NETosis findings in control group, active BD and inactive BD. Data shows as median (IQR). Mann-Whitney-U test; *p<0.05, **p≤0.01, ***p≤0.001, ns: not significant. (HC: healthy control, BD: Behçet disease, aBD: active BD, iBD: inactive BD, cf-DNA: cell free-DNA, NE: neutrophil elastase, MPO: myeloperoxidase, cit-H3: citrullinated histon_3)

Supporting image 3

Figure 2. Change in the levels of NETosis findings in longitudinal follow-up. Wilcoxon test; *p<0.05, **p≤0.01, ns: not significant. (BD: Behçet disease, aBD: active BD, iBD: inactive BD, cf-DNA: cell free-DNA, NE: neutrophil elastase, MPO: myeloperoxidase, cit-H3: citrullinated histon_3)


Disclosures: E. Bektas: None; R. Deniz: None; Z. Emrence: None; S. Ekmekci: None; N. Abacı: None; S. Amikishiyev: None; Y. Yalçınkaya: None; B. Artim Esen: None; M. Inanç: Boehringer-Ingelheim, 6, Pfizer, 6, UCB, 6; A. Gul: None.

To cite this abstract in AMA style:

Bektas E, Deniz R, Emrence Z, Ekmekci S, Abacı N, Amikishiyev S, Yalçınkaya Y, Artim Esen B, Inanç M, Gul A. The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-relationship-between-the-netosis-findings-and-disease-activity-in-behcet-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-between-the-netosis-findings-and-disease-activity-in-behcet-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology